Analysis of United States Drug Patent 10,023,560
Patent US 10,023,560, granted on July 17, 2018, to Merck & Co., Inc., describes novel compounds and their use in treating or preventing various diseases. The patent claims are directed to a genus of bicyclic heteroaryl compounds, specifically those containing a pyrazolopyridine core, and pharmaceutical compositions thereof. These compounds are characterized by their inhibitory activity against certain Janus kinase (JAK) enzymes.
What is the Core Innovation Claimed in US 10,023,560?
The central innovation patented in US 10,023,560 lies in the identification and synthesis of a specific class of chemical compounds. These compounds possess a bicyclic heteroaryl structure, with a core pyrazolopyridine moiety. The patent outlines a general chemical structure and specific exemplified compounds that exhibit inhibitory effects on JAK enzymes.
The general formula claimed is:
Formula (I)
R1
|
-----N-----
/ \
C C --- R2
|\ /|
| \ / |
C--N--C R3
| |
R4-----C
\ /
N--C
Where the substituents R1, R2, R3, and R4 are defined by specific chemical groups, and the pyrazolopyridine ring is further substituted. The patent details the preparation of numerous specific compounds falling within this broad definition.
Key structural features that are central to the claims include:
- Bicyclic Heteroaryl Core: The presence of a fused ring system containing nitrogen atoms within the rings.
- Pyrazolopyridine Moiety: A specific arrangement of a pyrazole ring fused to a pyridine ring.
- Substituent Diversity: The patent claims a range of possible substituents at defined positions on the core structure, allowing for a broad scope of potential compounds.
What Therapeutic Applications are Covered by the Patent?
US 10,023,560 claims therapeutic uses for the inventive compounds, primarily focusing on the modulation of JAK signaling pathways. The patent describes the utility of these compounds in treating or preventing diseases characterized by aberrant JAK activity.
The patent lists the following as indications for treatment or prevention:
- Inflammatory Diseases: This category includes conditions such as rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), and atopic dermatitis.
- Autoimmune Diseases: Conditions where the immune system attacks the body's own tissues, such as lupus erythematosus and multiple sclerosis.
- Myeloproliferative Disorders: Diseases characterized by the overproduction of blood cells, including myelofibrosis and polycythemia vera.
- Allergic Conditions: Such as asthma and allergic rhinitis.
- Certain Cancers: Specifically, those where JAK signaling plays a role in tumor growth or survival.
- Transplant Rejection: The use of these compounds to prevent the rejection of transplanted organs or tissues.
The mechanism of action is attributed to the inhibition of JAK enzymes. The patent specifically mentions JAK1, JAK2, JAK3, and TYK2 as targets. By inhibiting these kinases, the compounds are designed to disrupt downstream signaling pathways that contribute to inflammation and immune responses.
What are the Key Claims within US 10,023,560?
The patent contains multiple claims, ranging from specific compounds to broader categories and methods of use. The claims define the legal scope of protection.
Claim 1 (Independent): This claim defines a specific bicyclic heteroaryl compound of Formula (I) or a pharmaceutically acceptable salt thereof. The claim provides detailed definitions for the substituents R1, R2, R3, and R4, as well as the heterocyclic core. This is a broad claim encompassing a substantial number of chemical entities.
Example of Claim 1 Structure:
R1
|
-----N-----
/ \
C C --- R2
|\ /|
| \ / |
C--N--C R3
| |
R4-----C
\ /
N--C
Where R1, R2, R3, and R4 are defined with specific chemical functionalities, and the core is a substituted pyrazolopyridine.
Claim 2 (Dependent): This claim narrows down the scope of Claim 1, specifying particular substructures or substituents that must be present. For instance, it might define a specific atom or group at the R1 position.
Claim 3 (Dependent): Further refines Claim 1 or Claim 2 by adding additional structural limitations or specifying particular stereochemistry if applicable.
Claim 4 (Dependent): Similar to Claim 2 and 3, providing further specificity to the general structure.
Claim 5 (Independent): Claims a pharmaceutical composition comprising a compound of any of claims 1-4 and a pharmaceutically acceptable carrier. This claim protects the formulation aspect.
Claim 6 (Dependent): Specifies a particular type of pharmaceutical composition, such as a tablet, capsule, or injectable solution.
Claim 7 (Independent): Claims a method of treating or preventing a disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4. This claim covers the use of the patented compounds.
Claim 8 (Dependent): Specifies a particular disease or condition to be treated, such as rheumatoid arthritis or psoriasis.
Claim 9 (Dependent): Specifies a particular JAK enzyme (e.g., JAK1, JAK2) that the compound inhibits.
Claim 10 (Dependent): Claims a method of inhibiting a JAK enzyme, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any of claims 1-4.
The specific language of the substituents R1, R2, R3, and R4 is critical to the scope of the claims. These definitions would detail the types of atoms, functional groups, and ring structures that can be attached at these positions, determining which specific molecules are covered by the patent.
The patent also includes a substantial number of "exemplified compounds." These are specific chemical structures that have been synthesized and tested. While the claims are often broader, the exemplified compounds serve as concrete embodiments of the invention and can be crucial in infringement analysis and patent validity challenges.
What is the Patent Landscape for JAK Inhibitors?
The patent landscape for JAK inhibitors is crowded and competitive, reflecting the significant therapeutic potential of this drug class. Numerous companies hold patents covering different JAK inhibitor compounds, formulations, and therapeutic uses.
Key players in the JAK inhibitor space include:
- AbbVie: Holds patents related to upadacitinib (Rinvoq), a selective JAK1 inhibitor.
- Pfizer: Patented tofacitinib (Xeljanz), a JAK inhibitor used for rheumatoid arthritis and other autoimmune conditions.
- Eli Lilly and Company: Holds patents for baricitinib (Olumiant), a JAK1/JAK2 inhibitor.
- Incyte Corporation: Developed ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor for myelofibrosis and polycythemia vera.
- Gilead Sciences: Acquired patents related to filgotinib, a selective JAK1 inhibitor.
US 10,023,560, held by Merck & Co., Inc., contributes to this landscape by protecting a specific chemical series of JAK inhibitors. The patent's scope, particularly the breadth of the claimed general formula and the number of exemplified compounds, determines its potential impact on market entry for generic competitors and the development of new JAK-targeting therapies by other entities.
Comparison of JAK Inhibitor Patent Strategies:
| Company |
Key JAK Inhibitor |
Primary Target(s) |
Patent Strategy Focus |
| Pfizer |
Tofacitinib |
JAK1, JAK3 |
Compound, formulations, specific indications. |
| Eli Lilly |
Baricitinib |
JAK1, JAK2 |
Compound, selective dosing regimens, combination therapies. |
| AbbVie |
Upadacitinib |
JAK1 |
Highly selective compound, specific autoimmune diseases. |
| Incyte Corporation |
Ruxolitinib |
JAK1, JAK2 |
Compound, myeloproliferative disorders, graft-versus-host disease. |
| Merck & Co., Inc. |
(US 10,023,560) |
JAK1, JAK2, JAK3, TYK2 |
Broad structural genus, specific pyrazolopyridine core, various inflammatory and autoimmune diseases. |
The existence of US 10,023,560 means that any new drug development focusing on compounds falling within its claims, particularly those with the pyrazolopyridine core and specified substituents, would require careful freedom-to-operate analysis. The patent's expiration date is a critical factor for future market competition.
What is the Exclusivity Period for US 10,023,560?
United States patents typically have a term of 20 years from the date of filing, subject to maintenance fees. For US 10,023,560, filed on July 24, 2017, the 20-year term would expire on July 24, 2037.
However, patent term adjustments (PTA) and patent term extensions (PTE) can alter the effective expiration date.
- Patent Term Adjustment (PTA): This adjustment compensates for delays in the patent prosecution process caused by the U.S. Patent and Trademark Office (USPTO). The PTA is added to the standard 20-year term.
- Patent Term Extension (PTE): This is specifically for drug patents and is granted under the Hatch-Waxman Act to compensate for delays incurred during the FDA regulatory review process. The maximum PTE is typically 5 years, bringing the total potential patent life to 25 years from the filing date.
To determine the precise expiration date, one would need to consult the USPTO's Public PAIR system for any PTA granted and FDA records for any PTE awarded to the patent. Assuming no significant PTA or PTE, the patent would expire around July 24, 2037. This date is crucial for generic manufacturers planning to enter the market.
How Does US 10,023,560 Interact with Other Patents and Approvals?
The impact of US 10,023,560 on the market is influenced by its relationship with other intellectual property and regulatory approvals. If Merck has developed and gained FDA approval for a drug based on compounds claimed in this patent, then additional layers of protection, such as New Chemical Entity (NCE) exclusivity, may apply.
- NCE Exclusivity: Granted by the FDA upon approval of a new drug containing a novel active ingredient. This exclusivity period is typically 5 years and prevents the FDA from approving an ANDA (Abbreviated New Drug Application) for a generic version of the same drug.
- Data Exclusivity: Separate from patent protection, this is also granted by the FDA and prevents generic companies from relying on the innovator's clinical trial data for a specified period (e.g., 5 years for new formulations, 7 years for orphan drugs).
If a specific drug product is covered by multiple patents, the expiration of the earliest-expiring patent does not automatically allow for generic entry if later-expiring patents remain in force. The interplay between US 10,023,560, any related formulation patents, method-of-use patents, and regulatory exclusivities will dictate the precise timeline for generic competition.
Furthermore, the claims of US 10,023,560 must be analyzed in the context of prior art. If prior art is found that anticipates or renders obvious the claimed inventions, the patent's validity could be challenged, potentially leading to its invalidation or narrowed scope.
What is the Commercial Significance of this Patent?
The commercial significance of US 10,023,560 is directly tied to the therapeutic and commercial success of any drug product that falls under its patent claims. As a patent protecting a class of JAK inhibitors, its value is substantial, given the market size and therapeutic importance of this drug class.
If Merck has developed a successful JAK inhibitor compound within the scope of this patent, the patent provides a period of market exclusivity, allowing the company to recoup its R&D investments and generate significant revenue. The breadth of the claims will determine the extent to which it can prevent competitors from developing and marketing similar therapies.
The patent's claims cover a general chemical structure, implying that Merck could potentially develop multiple drug candidates within this chemical space. This offers strategic flexibility in its drug development pipeline.
The commercial implications include:
- Monopoly Period: The patent grants Merck the exclusive right to make, use, sell, and import the patented compounds and compositions for the duration of the patent term.
- Pricing Power: During the exclusivity period, the patent holder can set prices without direct competition.
- Licensing Opportunities: Merck could license its patent rights to other companies, generating revenue without direct market participation.
- Litigation Risk: Competitors may attempt to design around the patent claims or challenge its validity, leading to costly litigation.
The total market for JAK inhibitors is projected to grow significantly in the coming years, driven by increasing prevalence of autoimmune and inflammatory diseases. Patents like US 10,023,560 are therefore critical assets for companies operating in this space.
Key Takeaways
United States Patent US 10,023,560 protects a class of bicyclic heteroaryl compounds, specifically those with a pyrazolopyridine core, and their use in treating diseases mediated by JAK signaling. The patent claims a broad genus of compounds and pharmaceutical compositions thereof, targeting JAK1, JAK2, JAK3, and TYK2 enzymes. Therapeutic applications include inflammatory, autoimmune, myeloproliferative, and allergic conditions. The patent's term extends to approximately July 24, 2037, subject to potential adjustments and extensions, providing a significant period of market exclusivity for any associated drug products. The competitive landscape for JAK inhibitors is robust, and this patent represents a key intellectual property asset for Merck & Co., Inc.
Frequently Asked Questions
-
What specific JAK enzymes are targeted by the compounds claimed in US 10,023,560?
The patent claims compounds that inhibit JAK1, JAK2, JAK3, and TYK2 enzymes.
-
Does US 10,023,560 cover only specific drug compounds, or a broader class?
The patent covers a broad class of compounds defined by a general chemical formula, as well as numerous specific exemplified compounds.
-
What are the primary therapeutic areas covered by the patent's claims?
The patent claims are directed to the treatment of inflammatory diseases, autoimmune diseases, myeloproliferative disorders, allergic conditions, certain cancers, and prevention of transplant rejection.
-
When does US Patent 10,023,560 expire?
The patent's term is 20 years from its filing date of July 24, 2017, which would be approximately July 24, 2037, subject to adjustments and extensions.
-
Can generic versions of drugs based on compounds in US 10,023,560 be developed and marketed before the patent expires?
Generic entry before the patent's expiration is generally not possible if the drug is covered by the patent's claims, unless the patent is invalidated or expires earlier due to legal challenges or adjustments. Regulatory exclusivities may also impact generic market entry timelines.
Citations
[1] Merck & Co., Inc. (2018). United States Patent US 10,023,560 B2. U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Public PAIR. Retrieved from https://portal.uspto.gov/pair/PublicPair
[3] Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/therapeutic-equivalence-assessments/approved-drug-products-count-therapeutic-equivalence-evaluations-orange-book
